Boston Scientific Corp (BSX)
Pretax margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 1,984,000 | 1,929,000 | 1,565,000 | 1,484,000 | 1,194,000 | 866,000 | 1,104,000 | 908,000 | 1,078,000 | 991,000 | 281,000 | -48,000 | -350,000 | -4,609,000 | -4,291,000 | -3,966,000 | -3,532,000 | 513,000 | 878,000 | 1,079,000 |
| Revenue (ttm) | US$ in thousands | 13,974,000 | 10,508,000 | 10,348,000 | 9,999,000 | 9,228,000 | 12,104,000 | 11,689,000 | 11,502,000 | 11,625,000 | 11,168,000 | 10,855,000 | 9,774,000 | 9,553,000 | 9,751,000 | 9,790,000 | 10,420,000 | 10,349,000 | 10,035,000 | 9,758,000 | 9,649,000 |
| Pretax margin | 14.20% | 18.36% | 15.12% | 14.84% | 12.94% | 7.15% | 9.44% | 7.89% | 9.27% | 8.87% | 2.59% | -0.49% | -3.66% | -47.27% | -43.83% | -38.06% | -34.13% | 5.11% | 9.00% | 11.18% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $1,984,000K ÷ $13,974,000K
= 14.20%
Boston Scientific Corp.'s pretax margin has shown a positive trend over the past eight quarters, indicating improving profitability before taxes. In Q4 2023, the company achieved the highest pretax margin of 13.95%, reflecting efficient cost management and revenue generation. This represents a significant increase from Q1 2022, where the pretax margin was at 7.45%.
The consistent upward trajectory in pretax margin suggests that Boston Scientific Corp. has been successful in controlling operating expenses and maximizing profits before accounting for taxes. This improvement could be attributed to factors such as revenue growth, cost-cutting measures, operational efficiencies, or a combination of these elements.
Overall, the trend in the pretax margin indicates that Boston Scientific Corp. has been effectively managing its financial performance and is on a positive trajectory in terms of profitability.
Peer comparison
Dec 31, 2023